logo-loader
viewAdaptimmune Therapeutics PLC

Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancers

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) CEO James Noble and Co-Founder Helen Tayton-Martin tell Proactive Investors the US and UK-based cell therapy company is kicking off its SURPASS clinical trial with its SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform, that allows T-cells to target and destroy solid tumor cancers.

Noble and Tayton-Martin say the SURPASS trial will now begin enrolling up to 30 patients across multiple solid tumor indications in the US, hoping to complete enrollment at year end.

Quick facts: Adaptimmune Therapeutics PLC

Price: 9.23 USD

NASDAQ:ADAP
Market: NASDAQ
Market Cap: $1.42 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

23 hours, 36 minutes ago

2 min read